Paradigm Biopharmaceuticals Ltd has released a press release.
Half Year Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Quarterly Update and Appendix 4C
- PARs European Patent Granted for Bone Marrow Edema Lesions
- Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
- Paradigms ACL Phase 2 Clinical Trial Success
- PAR Successfully Completes A$5.75m Placement
Later from Paradigm Biopharmaceuticals
- Paradigm reports osteoarthritis pain reduced by 50%
- Paradigms phase 2 clinical data update
- Paradigm OA Phase 2b Clinical Trial over 80% Recruited
- PAR - 50% reduction in osteoarthritis pain maintained
- PAR achieves 100 per cent recruitment in Phase 2b OA Trial
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals